Gabriele Zoppoli was born in Genoa on January 9th, 1981. He graduated summa cum laude in Medicine and Surgery in 2005 and is a specialist in Internal Medicine, a T.D.B Researcher at the University of Genoa, and a Medical Manager of the first level in the Internal Medicine Unit with Oncological Focus at the Policlinico San Martino IRCCS Hospital in Genoa. Gabriele Zoppoli was a Visiting Researcher at the Laboratory of Molecular Pharmaceutics, directed by Dr. Yves Pommier, at the National Cancer Institute in Bethesda (MD) in 2009-10. During this period, he deepened his knowledge of high-dimensional microarray analysis techniques and discovered a protein, SLFN11, causally implicated in chemotherapy resistance. Currently, SLFN11 is being validated, in collaboration with AstraZeneca UK (Winkler C et al., available on bioRxiv at https://doi.org/10.1101/2020.05.22.110593) as a biomarker of response to different drugs used in oncology practice (Zoppoli G et al. Proc Natl Acad Sci U.S.A. 2012). Gabriele Zoppoli obtained his PhD in Clinical and Experimental Oncology and Hematology in 2012, with the support of a My First AIRC Grant for his research projects. He then spent two years (2014-15) as a Research Fellow at the Institut Jules Bordet in Brussels, where he contributed to the characterization of the genomic landscape of lobular breast carcinoma (Desmedt C, Zoppoli G et al. J Clin Oncol 2016). Since 2015, Gabriele Zoppoli has been responsible for Scientific Relations between the Breast International Group, the largest European network dedicated to clinical research on breast cancer, and the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), the oldest non-profit Italian clinical cooperative group in oncology. Since 2018, he has been a member of the GOIRC Board of Directors (https://www.goirc.org/it/chi%2dsiamo/consiglio%2ddirettivo/1-3704-1-).

Since 2020, Gabriele Zoppoli has been a member of the Molecular Tumor Board of the Policlinico San Martino Hospital, as an expert clinical manager in Molecular Biology. Gabriele Zoppoli is a member of more than ten Executive Committees of international phase II/III clinical and translational studies on the treatment of breast cancer, and is a member of the Data Analysis Committee of AURORA, the largest European platform for multicenter prospective molecular characterization of advanced breast cancer (over 1000 patients recruited as of July 2020). Gabriele Zoppoli is the author of more than 60 indexed papers in international journals and is an Associate Section Editor of the Journal of Translational Medicine and an Associate Editor of Tumori Journal. Gabriele Zoppoli will be responsible for aspects related to the analytical and clinical validation of the ONCO-ORACLE platform. In particular, Gabriele Zoppoli is the Principal Investigator of RENOVATE, a translational clinical study funded by the AIRC Foundation. The aim of this study, which will collect plasma, mononuclear cells, exosomes, urine samples, and radiological images from over 800 women who undergo mammography with suspicious findings for small breast adenocarcinoma, is to compare innovative non-invasive techniques studied in the ONCO-ORACLE